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In this study, we tested whether the human heart possesses a
cardiac stem cell (CSC) pool that promotes regeneration after
infarction. For this purpose, CSC growth and senescence were
measured in 20 hearts with acute infarcts, 20 hearts with end-stage
postinfarction cardiomyopathy, and 12 control hearts. CSC number
increased markedly in acute and, to a lesser extent, in chronic
infarcts. CSC growth correlated with the increase in telomerase-
competent dividing CSCs from 1.5% in controls to 28% in acute
infarcts and 14% in chronic infarcts. The CSC mitotic index in-
creased 29-fold in acute and 14-fold in chronic infarcts. CSCs
committed to the myocyte, smooth muscle, and endothelial cell
lineages increased 85-fold in acute infarcts and 25-fold in
chronic infarcts. However, p16INK4a-p53-positive senescent CSCs
also increased and were 10%, 18%, and 40% in controls, acute
infarcts, and chronic infarcts, respectively. Old CSCs had short
telomeres and apoptosis involved 0.3%, 3.8%, and 9.6% of CSCs in
controls, acute infarcts, and chronic infarcts, respectively. These
variables reduced the number of functionally competent CSCs from
26,000cm3 of viable myocardium in acute to 7,000cm3 in
chronic infarcts, respectively. In seven acute infarcts, foci of spon-
taneous myocardial regeneration that did not involve cell fusion
were identified. In conclusion, the human heart possesses a CSC
compartment, and CSC activation occurs in response to ischemic
injury. The loss of functionally competent CSCs in chronic ischemic
cardiomyopathy may underlie the progressive functional deterio-
ration and the onset of terminal failure.
cardiac progenitor cells  human heart  myocardial infarction
Myocardial regeneration occurs in humans after ischemicinjury (1, 2), and myocyte proliferation appears to be
restricted to the viable myocardium adjacent to and remote from
the infarct (2). The identification of cardiac stem cells (CSCs) in
the adult heart (3–7) suggests that replicating myocytes may
constitute a subpopulation of rapidly growing amplifying cells
originated from more primitive cells. CSCs are distributed
throughout the heart, raising the possibility that those located
within the infarct or in its proximity could divide and differen-
tiate reconstituting dead myocardium. If this hypothesis were the
case, strategies may be developed to enhance myocardial growth
promoting partial restoration of the infarct. This response would
reduce infarct size, improve function, and decrease mortality.
Myocardial regeneration within the infarct could have escaped
earlier observations because the heart was not viewed as a
self-renewing organ, and myocyte replacement was considered
to be regulated by a subset of cells capable of a few rounds of
doubling, located by necessity in the spared portion of the
ventricle (2). Alternatively, the lack of myocardial regeneration
might reflect CSC death within the infarct andor the inability
of CSCs to migrate and reach the necrotic area. Thus far, no
evidence has been presented that CSCs can reconstitute in-
farcted tissue in the human heart.
Myocyte division is markedly reduced in chronic ischemic
cardiomyopathy (1, 2), and the recognition that CSCs modulate
cardiac homeostasis (3–6) suggests that a decrease in number
and growth of CSCs may underlie the attenuation in cell
multiplication in long-term heart failure. In this study, we
investigated whether CSCs divide and differentiate in myocytes
and vascular cells acutely after infarction and whether defects in
CSC number andor function promote a decline in myocyte and
vessel regeneration chronically. CSC activation was evaluated by
markers of cell proliferation (8, 9) together with histone H3
phosphorylation (10) as amarker of mitosis. CSC senescence was
determined by the expression of aging-associated proteins and
the presence of DNA oxidative stress and apoptosis (11, 12). The
telomere–telomerase system was investigated because of its
effects on cell growth and viability (13).
Materials and Methods
Patients and CSCs. We studied hearts from patients who died
acutely after infarction, and hearts from patients who underwent
cardiac transplantation after chronic infarcts (Fig. 7 and Table
1, which are published as supporting information on the PNAS
web site). CSCs were identified by c-kit, MDR1, and Sca-1-like
epitopes (Fig. 8 and Table 2, which are published as supporting
information on the PNAS web site). CSCs were negative for
transcription factors and structural proteins of cardiac cell
lineages and for markers of cells of hemopoietic origin. CSC
number and volume were then determined (Supporting Materials
and Methods, which is published as supporting information on
the PNAS web site).
CSC Death and Growth. Telomere length in CSCs was evaluated by
quantitative fluorescence in situ hybridization. In each heart, 50
CSC nuclei were examined for telomeric length, and 100–200
CSC nuclei for p53 and p16INK4a. X and Y chromosomes were
detected by fluorescence in situ hybridization with CEP X
-satellite and CEP Y satellite III DNA probes. CSC apoptosis
was evaluated by Hairpin 1 and CSC proliferation by Ki67,
MCM5, and phospho-histone H3. Western blotting of proteins
implicated in CSC senescence, telomere function, and CSC
growth was obtained (Supporting Materials and Methods).
Results
CSC Number. CSCs were lineage-negative cells with a volume of
203 50m3. In all hearts,60%of CSCs expressed c-kit,MDR1,
and Sca-1-like epitopes together, and only small percentages of
CSCs possessed one or two antigens (Fig. 1A). CSCs were negative
for markers of hematopoietic cell lineages, indicating that, at most,
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: CSC, cardiac stem cell; EC, endothelial cell; MI, myocardial infarction; SMC,
smooth muscle cell; TERT, telomerase.
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a very small fraction of primitive cells could have been of bone
marrow origin. Additionally, the Sca-1-like positive CSCs were
negative for Ets1, Erg1, flk1, VE-cadherin, and von Willebrand
factor excluding the contribution of endothelial cells to the CSC
pool. The Sca-1-like protein was detected by Western blotting in
human, dog, and rat myocardium and in human bone marrow,
endothelial cells, and peripheral blood. The band molecular weight
was identical to that identified in mouse heart, kidney, and spleen.
Moreover, Sca-1-like positive cells were found in human bone
marrow (Fig. 9, which is published as supporting information on the
PNAS web site). Because members of the Ly6 protein family were
found in humans (14, 15), the Sca-1 antibodymay have reacted with
an epitope of human CSCs that corresponds to a known or
unknown member of the Ly6 family.
Fig. 1. Heart failure and CSCs. Shown are the expression of surface epitopes (A) in CSCs and the number of CSCs per cm3 of viable myocardium (B). *, P 0.05
vs. controls (C); **, P  0.05 between the border and remote myocardium in acute myocardial infarction (MI). †, P  0.05 between acute and chronic MI. (C)
Expression of TERT in human cardiac protein lysates from control (C), acute (A), and chronic (Ch) infarcted hearts. (D) TERT activity measured by the telomeric
repeat amplification protocol assay. Products of TERT activity start at 50 bp and display a 6-bp periodicity. Samples treated with RNase () were used as a negative
control and HeLa cells as a positive control. Serial dilutions of proteins (0.5 and 1.0 g) were used to confirm the specificity of the reaction. The band at 36 bp
corresponds to an internal control for PCR efficiency. (E) Expression of phospho-Akt and total Akt; (F) unphosphorylated (filled arrowhead) and phosphorylated
(open arrowhead) forms of TERT in an Akt kinase assay. (G) Expression of the telomere-related proteins, TRF-1, TRF-2, and DNA-PK (DNA-PKcs, Ku86, and Ku70),
and full-length and cleaved poly (ADP-ribose) polymerase. (H) Expression of cell cycle inhibitors and markers of cellular senescence. Optical density values are
shown in Fig. 10.
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The number of CSCs in the viable myocardium of infarcted
hearts was increased. However, in acute infarcts, there were
40,000 CSCs per cm3 of tissue in the border zone and 20,000
per cm3 of myocardium in the remote region. In chronic infarcts,
in which a border zone was no longer present, the number of
CSCs was lower than in acute infarcts (Fig. 1B). Thus, ischemic
heart failure led to an increase in the CSC number that was
attenuated with time.
Telomerase Function. Telomerase (TERT) protects from the loss
of DNA at the chromosomal ends during cell division (13,
16–18). TERT expression and activity provide an index of the
growth potential of CSCs and their committed progeny, includ-
ing amplifying myocytes, endothelial cell (EC), and smooth
muscle cell (SMC) progenitors (19). In comparison with con-
trols, TERT did not vary in acute infarcts but decreased 72% in
chronic infarcts (Fig. 1C). TERT activity increased 8.6-fold in
acute and 2.6-fold in chronic infarcts (Fig. 1D). Because Akt
activates TERT (20), the quantity and degree of phosphorylation
of Akt were evaluated. Total Akt was similar in control and
infarcted hearts, but the phosphorylated form increased 21-fold
in acute and 3.8-fold in chronic infarcts (Fig. 1E). To test
whether phospho-Akt activated TERT, a peptide containing the
Akt-phosphorylation site of human TERT was used in an
Akt-kinase assay (20). TERT phosphorylation increased in acute
infarcts (Fig. 1F; Fig. 10, which is published as supporting
information on the PNAS web site). Phospho-Akt was detected
in 60  12% and 13  11% c-kit-positive cells in acute and
chronic infarcts, respectively. A value of 9  3% was found in
control hearts. Thus, telomerase activity was enhanced acutely
and, to a lesser extent, chronically after infarction, and this
difference correlated with the difference in active Akt.
Telomeric Shortening and CSC Senescence and Death. Telomeres are
protected by a complex of proteins including TRF1, TRF2,
uncleaved PARP, and DNA-PK. The levels of TRF2, full-length
PARP, and DNA-PK decreased after infarction but significantly
more in chronic than in acute infarcts (Figs. 1G and 10).
Conversely, cleaved inactive-PARP increased more in chronic
than in acute infarcts (Fig. 1G). These molecular modifications
were accompanied by increased expression of p14ARF and
p16INK4a, phosphoSer-15-p53 and p53. p14ARF inhibits p53 deg-
radation, and p16INK4a inhibits cdk4 and cdk6, blocking cells at
the G0-G1 boundary (11). Moreover, p53 inhibits the cell cycle
at G1-S or G2-M checkpoint. Additionally, the cyclin-dependent
G1 kinase inhibitors p21Cip1 and p27Kip1 decreased acutely after
infarction, whereas in chronic infarcts, p21Cip1 decreased but
p27Kip1 increased (Figs. 1H and 10). Bmi-1, a negative modulator
of the age-associated genes p14ARF and p16INK4a, decreased
more in chronic than in acute infarcts. Thus, telomere dysfunc-
tion, cellular senescence, and the expression of genes that
interfere with cell replication and activate cell death were
enhanced predominantly in chronic heart failure.
Because of these biochemical alterations, the percentage of
CSCs that reached growth arrest and senescence was deter-
mined. This finding enabled us to define the pool of functionally
competent CSCs. Three markers of cellular senescence were
used: p16INK4a, p53, and telomeric shortening (Fig. 2). In com-
parison with control hearts, the fraction of p16INK4a-positive
CSCs increased an average of 1.7-fold in acute and 3.6-fold in
chronic infarcts (Fig. 11, which is published as supporting
information on the PNAS web site). p53 was present in a smaller
fraction of CSCs, and most p53-positive CSCs coexpressed
p16INK4a. Moreover, the number of p16INK4a-p53-positive CSCs
with short telomeres increased markedly in chronic and to a
lesser extent in acute infarcts (Fig. 12, which is published as
supporting information on the PNAS web site). Also, CSC
apoptosis increased an average of 12-fold in acute and 32-fold in
chronic infarcts (Fig. 13, which is published as supporting
information on the PNAS web site). Apoptotic CSCs were
p16INK4a-p53 positive, and 80% exhibited oxidative damage
detected by 8-OHdG in the nuclei. As a result, functionally
competent CSCs were 73% lower in chronic (6,900 1,100 cells
per cm3 myocardium) than in acute (25,600  3,600) infarcts.
However, the value in chronic infarcts was higher than in
controls (3,500  500). Thus, oxidative stress, telomeric short-
ening, p16INK4a, p53, and apoptosis coexist in CSCs, reducing
their functional pool size in chronic heart failure.
CSC Growth and Differentiation. To assess the magnitude of on-
going CSC growth in infarcted hearts, the number of cycling
telomerase-competent CSCs was determined. Two cell-cycle
markers were used, Ki67 and MCM5 (Fig. 3 A–D; Fig. 14, which
is published as supporting information on the PNAS web site).
In comparison with controls, the fraction of telomerase-Ki67-
positive CSCs increased an average of 19-fold in acute and 9-fold
in chronic infarcts (Fig. 3E). Slightly higher values were obtained
with MCM5. Mitotic CSCs, recognized by histone H3 phosphor-
ylation (Fig. 3 F–I), increased 26-fold in acute and 13-fold in
chronic infarcts (Fig. 3J). Thus, the activation of CSCs was
significantly greater acutely than chronically after infarction.
Because of the difficulty to separate in the human heart
preexisting myocytes and vascular structures from those gener-
ated by activation and differentiation of CSCs, we analyzed the
coexpression of stem cell antigens with transcription factors and
cytoplasmic proteins specific for cardiomyocytes, SMCs, and
ECs. Therefore, the commitment of CSCs to myocytes, SMCs,
and ECs was established (Fig. 4 A–C; Fig. 15, which is published
as supporting information on the PNAS web site). The more
Fig. 2. Heart failure and CSC senescence. c-kit positive CSCs (green, A–F)
express p16INK4a (yellow, A and B) and p53 (magenta, C and D). The detection
of telomeres in c-kit-positive CSCs is shown by small white fluorescence dots (E
and F). Shown are control myocardium (A), acute infarcts (CandE), and chronic
infarcts (B, D, and F). (Scale bars: 10 m.)
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mature phenotype of these cells cannot be easily linked to the
CSC population because the stem cell antigens are lost early
during differentiation (3). However, maturing myocytes lacking
stem cell antigens and newly formed arterioles with a thick wall
and small lumen were recognized (Fig. 16, which is published as
Fig. 3. Heart failure and CSC growth. (A–D) c-kit-positive CSCs (green,
arrows) express telomerase (red dots, A and C) and MCM5 (white dots, B) or
Ki67 (yellow dots, D). Myocytes are labeled by -sarcomeric actin (red) and
nuclei by DAPI (blue). (E) Percentage of telomerase competent CSCs in the cell
cycle. (F–I) c-kit-positive CSCs (green) have nuclei labeled by phospho-H3 (red).
(J) Mitotic index of CSCs. *, P 0.05 vs. controls (C); **, P 0.05 between the
border and remote myocardium in acute MI; †, P  0.05 between acute and
chronic MI. A, B, and F–I are acute infarcts. (Scale bars: 10 m.)
Fig. 4. Heart failure and lineage commitment of CSCs. (A–C) Myocyte
progenitors (A) express c-kit (green) and the myocyte transcription factor
MEF2C (yellow dots); myocyte precursors (B) express c-kit (green), MEF2C
(yellow dots) and have a thin layer of cytoplasm positive for-sarcomeric actin
(red). (C) Small developing myocytes (-sarcomeric actin, red) express MEF2C
(yellow dots) and have lost the stem cell surface antigen. Connexin 43 is
detected between some of these maturing cells (green, arrows). (D) Myocyte
progenitors and precursors. *, P  0.05 vs. controls (C); **, P  0.05 between
the border and remote myocardium in acute MI; †,P0.05 between acute and
chronic MI. Shown are acute infarcts (A and C) and a chronic infarct (B). (Scale
bars: 10 m.)
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supporting information on the PNAS web site). The number of
myocyte progenitorsprecursors increased an average of 90-fold
in acute infarcts and 26-fold in chronic infarcts (Fig. 4D). Similar
increases were found in SMC and EC progenitorsprecursors
(Fig. 17, which is published as supporting information on the
PNAS web site). Thus, activation and commitment of CSCs was
robust in acute infarcts but markedly attenuated in chronic
infarcts.
Myocardial Regeneration. The identification of human CSCs
raised the possibility that some of these cells located at the
border of the infarct or within the infarct may survive the
ischemic event and initiate cardiac repair. Seven of the 20 acutely
infarcted hearts exhibited areas of spontaneous and intense
myocardial regeneration invading the dead tissue (Fig. 5; Fig. 18,
which is published as supporting information on the PNAS web
site). These foci varied from 500 m2 to 5 mm2 and consisted of
clusters of proliferating myocytes, and SMCs and ECs organized
in small new coronary vessels; these regenerated cells were
negative for apoptosis. A similar phenomenon was not found in
chronic infarcts. Regenerated myocytes were not the product of
fusion between CSCs and spared myocytes because, in male
hearts, they possessed only one X and one Y chromosome and,
in female hearts, only two X chromosomes (Fig. 6). Thus, the
heart has an intrinsic growth reserve capable of repairing dead
myocardium independently of cell fusion.
Discussion
The results of this study indicate that the human heart contains
a population of CSCs that can divide and differentiate into
myocytes, and SMCs and ECs organized in coronary vessels. The
CSC pool is enhanced acutely after infarction, but this growth
response is attenuated in chronic heart failure. In the latter case,
telomerase activity is decreased, and CSC division is impaired by
severe telomeric shortening and cellular senescence. Moreover,
CSC apoptosis is increased, resulting in a decline of the number
of functionally competent CSCs. Therefore, the formation of
myocytes and coronary vasculature cannot counteract the
chronic loss of parenchymal cells and vascular structures (21–
23). We propose that this negative balance between myocardial
regeneration and death leads to progressive ventricular dilation
and deterioration of ventricular performance (24). Nevertheless,
the recognition that the human heart possesses a stem cell
compartment that, although compromised, is still present in
end-stage failure points to strategies for the treatment of the
human disease. It might be possible to isolate CSCs from small
samples of myocardium and, after their growth in vitro, the
expanded CSCs can be administrated back to the same patient.
This therapeutic approach would have all of the advantages of
autologous transplantation.
Myocardial regeneration acutely after infarction appears to be
mediated by multipotent CSCs, which undergo lineage commit-
ment and form amplifying cells that divide and mature. Whether
these cells acquire functional competence and adult character-
istics cannot be established at present. However, this possibility
is supported by prior observations in animals in which the
injection of CSCs in the infarcted myocardium results in the
reconstitution of the dead tissue and improvement in cardiac
function (5). The newly formed, small, developing myocytes
found in experimental animals have the same dimensional and
structural characteristics of those detected in the foci of spon-
Fig. 5. Heart failure and myocardial regeneration. (A) Area of regenerating
myocardium within the infarct. Clusters of highly proliferating small devel-
oping myocytes are visible. Myocytes are labeled by cardiac myosin (red) and
nuclei by DAPI (blue). Most of these cells are positive for MCM5 (white). Two
dividing small myocytes are shown in Insets. (B) Cluster of cells included in a
rectangle in the middle of an acute infarct. These cells are shown at higher
magnification in C andD. They represent c-kit-positive cells (green, arrows) at
times expressing cardiac myosin (red; D). (Scale bars: A and B, 100 m; C and
D, 10 m.)
Fig. 6. Myocardial regeneration and cell fusion. Regenerating myocytes in
a male (A) and female (B) infarcted heart. In the male heart, only one X
(magenta) and one Y (green) chromosome are detected. In the female heart,
only two X chromosomes (magenta) are visible. (Scale bars: 10 m.)
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taneous cardiac repair in humans. These neonatal-like myocytes
are functional and have contractile properties equal or superior
to those of the spared hypertrophied myocytes (5). However,
acutely after infarction, the magnitude of the infarct may exceed
the response of CSCs and tissue reconstitution so that cardio-
genic shock supervenes (25). Despite this negative clinical
outcome, the identification of spontaneous myocardial regener-
ation in acute infarcts demonstrates that dead tissue can be
replaced partly by new myocardium derived from the activation
of endogenous progenitor cells. These data extend previous
observations in pressure hypertrophy in humans (3) and point to
a critical role of CSCs in cardiac repair.
The mechanism by which viable myocardium can be formed in
a region with little or no blood supply and unfavorable environ-
ment is unclear. Opening of collateral vessels can provide
enough oxygen for cell growth and function and explain the
presence of CSCs within the infarct. Similarly, oxygen diffusion
from the blood in the left ventricular chamber to the endom-
yocardium can preserve progenitor cells in the ischemic region.
Alternatively, CSCs can migrate from the surviving myocardium
to the infarct and differentiate into myocytes and coronary
vessels (5, 26).
The exogenous administration of progenitor cells of bone
marrow origin in patients with ischemic cardiomyopathy has
been found to ameliorate ventricular remodeling and cardiac
performance (27). Whether these beneficial effects on the
postinfarcted heart are mediated by differentiation of hemato-
poietic cells into cardiomyocytes and coronary vessels (28) or the
injected cells secrete factors that activate the local CSCs has not
been resolved yet. As has been suggested, both mechanisms may
be involved (27). This positive paracrine loop points to the
importance of CSC growth as a therapeutic strategy for the
restoration of lost myocardium. The current observations in
humans, together with the replacement of infarcted tissue by
activation and differentiation of resident CSCs in animals,
indicate that the CSC may be the ideal cell for myocardial
regeneration. Clones of human CSCs have been published in ref.
26. The presence of stem cells that reside in the heart, and are,
therefore, predestined to become cardiac cells, should result in
more efficient regeneration and obviate the need for the more
complex and time-consuming process involved in the commit-
ment to cell lineages different from the organ of origin (29). A
rapid regeneration of irreversibly altered myocardium is crucial
with large infarcts in which the immediate reduction of infarct
size is critical for survival (25).
Whether CSCs are generated within the myocardium or are
continuously supplied to the heart by the bone marrow through
the systemic circulation cannot be completely resolved. How-
ever, the notion that hematopoietic stem cells (HSCs) migrate
and repopulate distant organs such as the heart is not supported
by available information. The absence or minimal trafficking of
HSCs from the bone marrow to the myocardium has been shown
in the normal and pathologic heart (26). Moreover, the lack of
comorbidity of heart failure and bone marrow failure in the same
patient population does not point to a critical function of the
bone marrow in myocardial regeneration. Conversely, the dem-
onstration that human CSCs can acquire the phenotype of
cardiomyocytes, SMCs, and ECs establishes a mechanistic link
between the morphological findings and the proposed crucial
role of this cell population in vivo. In this regard, a large number
of developing myocytes (10,000 cells per g), SMCs (1,100 cells
per g) and ECs (3,500 cells per g) was measured in the border
zone acutely after infarction. The contribution of cell regener-
ation within the infarct was significantly less and was docu-
mented only in a few cases. Cell regeneration decreased 70%
chronically after infarction, providing an important element for
terminal failure. The reduction in the CSC compartment ap-
peared to be the consequence of replicative senescence and
growth arrest together with apoptosis. This view is consistent
with the marked shortening of telomeres and the increased
expression of p16 and p53. The duration of the cardiac disease,
coupled with the compensatory long-term replicative growth of
CSCs, may have led to telomere attrition, activation of the p53
and p16 pathways and, ultimately, to the senescent phenotype.
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